Search results
Results from the WOW.Com Content Network
Eperisone hydrochloride is available as the brand name preparations Myonal and Epry as 50 mg sugar-coated tablets, or as 10% granules for oral administration. [6] An experimental form of the drug, as a transdermal patch system, has shown promising results in laboratory tests on rodents; however, this product is not currently available for human use.
Fluoxetine, sold under the brand name Prozac, among others, is an antidepressant medication of the selective serotonin reuptake inhibitor (SSRI) class [2] used for the treatment of major depressive disorder, anxiety, obsessive–compulsive disorder (OCD), panic disorder, premenstrual dysphoric disorder, and bulimia nervosa. [2]
Free shipping with no order minimum. Save $0.10 per gallon on gas at 14,000+ locations nationwide. Stream over 40,000 shows with a Paramount+ subscription that's included with your Walmart+ ...
Modified-release dosage is a mechanism that (in contrast to immediate-release dosage) delivers a drug with a delay after its administration (delayed-release dosage) or for a prolonged period of time (extended-release [ER, XR, XL] dosage) or to a specific target in the body (targeted-release dosage).
About one-quarter of U.S. adults over age 50 say they expect to never retire and 70% are concerned about prices rising faster than their income, an AARP survey finds. About 1 in 4 have no ...
Dosage forms (also called unit doses) are pharmaceutical drug products presented in a specific form for use. They contain a mixture of active ingredients and inactive components ( excipients ), configured in a particular way (such as a capsule shell) and apportioned into a specific dose .
Cyproterone acetate (CPA), sold alone under the brand name Androcur or with ethinylestradiol under the brand names Diane or Diane-35 among others, is an antiandrogen and progestin medication used in the treatment of androgen-dependent conditions such as acne, excessive body hair growth, early puberty, and prostate cancer, as a component of feminizing hormone therapy for transgender individuals ...
The paper's co-principal investigator, Dr. J. Michael Gaziano, a cardiologist, was quoted by The New York Times as saying "it certainly appears there is a modest reduction in the risk of cancer from a typical multivitamin." [4] The study was also featured in The Wall Street Journal on October 17, 2012. [5]